晚期卵巢癌的新治疗方案有可能显着改变英国的治疗途径。了解多学科团队/肿瘤委员会 (MDT) 的结构和职责以及区域差异将使服务能够更有效地适应这些变化。KNOW-OC 调查于 2020 年进行，旨在了解选定的 66 名医疗保健专业人员的观点（英国医院参与晚期卵巢癌护理的 HCP。结果显示，MDT 在晚期卵巢癌治疗中的参与因途径阶段和复发线而异，98.5% 的 HCP 表示 MDT 参与了最初的决策但对于多次复发的患者，这一比例仅为 40.9%。 75.8% 的受访者表示，MDT 主要负责确定患者是否接受初次或间期细胞减灭术，大多数 HCP (80.3%) 表示肿瘤播散模式是影响这一决定的最重要因素。调查时最常评估的生物标志物是 CA125、gBRCA 和 tBRCA。同源重组缺陷被认为是决定预后的第二重要因素，但在调查完成时很少有中心能够进行检测。预计主动监测的使用将减少，有利于一线靶向治疗。几乎所有 (98.5%) 的 HCP 都同意二次细胞减灭手术在治疗复发方面发挥着作用（针对精心挑选的患者）。结果强调了 HCP 对 MDT 参与和具体实践的看法存在英国特定的地理差异，例如分子生物标志物检测以及整体治疗方法。总之，这些发现提高了对英国各地报告的卵巢癌临床实践的理解，并提供了与最佳实践建议更新相关的决策的见解（例如欧洲肿瘤内科学会/欧洲妇科肿瘤学会共识声明）和引入新的治疗方案。版权所有 © 2023。由 Elsevier Ltd 出版。

New treatment options for advanced ovarian cancer have the potential to significantly change the treatment pathway in the UK. Understanding the structures and responsibilities of multidisciplinary teams/tumour boards (MDT) and regional variations will enable services to adapt more effectively to these changes.The KNOW-OC survey was conducted in 2020 to understand the views of a selected group of 66 healthcare professionals (HCPs) involved in advanced ovarian cancer care in UK hospitals.The results showed that MDT involvement in the management of advanced ovarian cancer varied depending on pathway stage and line of relapse, with 98.5% of HCPs responding that the MDT was involved in decisions at initial presentation, but only 40.9% for patients with multiple relapses. The MDT was mostly responsible for determining whether the patients would undergo primary or interval cytoreductive surgery according to 75.8% of respondents, and most HCPs (80.3%) stated that tumour dissemination patterns were the most important factor influencing this decision. The most commonly assessed biomarkers at the time of the survey were CA125, gBRCA and tBRCA. Homologous recombination deficiency was viewed as the second most important factor for determining prognosis, but few centres had access to testing at the time of survey completion. The use of active surveillance was expected to decrease in favour of first-line targeted therapies. Nearly all (98.5%) HCPs agreed there is a role for secondary cytoreductive surgery for the treatment of recurrence (for carefully selected patients).The results highlighted UK-specific geographical variation in the views of HCPs on MDT involvement and specific practices, such as molecular biomarker testing, and the overall treatment approach. Together, these findings improve the understanding of reported clinical practice across the UK for ovarian cancer and provide insight into decision-making associated with updates to recommendations for best practice (e.g. European Society for Medical Oncology/European Society of Gynaecological Oncology consensus statements) and the introduction of new treatment options.Copyright © 2023. Published by Elsevier Ltd.